CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor–based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma

Journal:

European Urology

Published:

2025-10-01

DOI:

10.1016/j.eururo.2025.07.018

Affiliations:

14

Authors:

13

Go to article

Institutions	Authors	Share
Ipsen Group, France	2.000000	0.15
Mount Vernon Cancer Centre, United Kingdom (UK)	1.000000	0.08
Essen University Hospital, Germany	1.000000	0.08
University Hospital Carl Gustav Carus Dresden, TU Dresden, Germany	1.000000	0.08
Queen Mary University of London (QMUL), United Kingdom (UK)	1.000000	0.08
Institute Gustave-Roussy (IGR), France	1.000000	0.08
Cancer Research Center of Marseille (CRCM), France	1.000000	0.08
Ipsen Germany, Germany	1.000000	0.08
Bern University Hospital, Switzerland	1.000000	0.08
Klinikum Stuttgart, Germany	1.000000	0.08
University of Regensburg (UR), Germany	0.500000	0.04
Caritas-Krankenhaus St. Josef, Germany	0.500000	0.04
Beatson West of Scotland Cancer Centre (BWoSCC), United Kingdom (UK)	0.500000	0.04
University of Glasgow, United Kingdom (UK)	0.500000	0.04

Interested in Oncology and Carcinogenesis?